TG Therapeutics (TGTX)
Biotech
Close on Nov 10, 2026 (from our latest Long View update): $64.26
- Market value
- $9.7Bat the Nov 10 close
- Revenue growth
- +69%12 months to Sep 30, 2026 (10-Q)
- FCF margin
- 10%12 months to Sep 30, 2026 (10-Q)
- Net debt
- $189Mat Sep 30, 2026
- Worst fall since listing
- −99.6%May 4, 2010 to Dec 29, 2011; not back to that high (−72.2% now)
About the company
Website (external site)Investor relations (external site)SEC filings (external site)
The Long View
TG was a cancer-drug developer until April 2022, when it announced the withdrawal of its lymphoma drug Ukoniq and the combination filing in leukaemia after trial survival data turned against it.
▲ better · ▼ worse · ⚠ watch · ● unchanged, latest quarter · share count · cash
Updated Nov 11, 2026
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
Long-term fundamentals
Annual results for TG Therapeutics, FY2011–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $0.2M in FY2016 to $616M in FY2025.
Free cash flow was positive in 0 of the 15 years shown; FY2025: −$25M.
Margins
Operating margin was 20% in FY2025, vs −179996% in FY2020.
Diluted share count
The diluted share count rose 40% from FY2020 to FY2025, to 161M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $616M | — | 20% | $447M | −$25M | $0.2M | −$25M |
| FY2024 | $329M | — | 13% | $23M | −$41M | $0.0M | −$41M |
| FY2023 | $234M | — | 9% | $13M | −$31M | $0 | −$31M |
| FY2022 | $3M | — | −7839% | −$224M | −$176M | $0.0M | −$176M |
| FY2021 | $7M | — | −5154% | −$348M | −$296M | $0.4M | −$296M |
| FY2020 | $0.2M | — | −179996% | −$279M | −$215M | $0.4M | −$215M |
| FY2019 | $0.2M | — | −111220% | −$173M | −$133M | $0.1M | −$133M |
| FY2018 | $0.2M | — | −114737% | −$173M | −$129M | $0.1M | −$129M |
| FY2017 | $0.2M | — | −78100% | −$118M | −$94M | $0.0M | −$94M |
| FY2016 | $0.2M | — | −51953% | −$78M | −$62M | $0.3M | −$62M |
| FY2015 | — | — | — | −$63M | −$45M | $0.0M | −$45M |
| FY2014 | — | — | — | −$56M | −$35M | $0.0M | −$35M |
| FY2013 | — | — | — | −$20M | −$11M | $0.0M | −$11M |
| FY2012 | — | — | — | −$18M | −$5M | $0.0M | −$5M |
| FY2011 | — | — | — | −$0.9M | −$0.1M | $0 | −$0.1M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 161M | $142M | $246M | $65M | — | $91M |
| FY2024 | 160M | $311M | $244M | $43M | — | $9M |
| FY2023 | 149M | $218M | $100M | $38M | — | $0 |
| FY2022 | 135M | $162M | $71M | $45M | — | $0 |
| FY2021 | 132M | $315M | $68M | $61M | — | — |
| FY2020 | 115M | $605M | $30M | $80M | — | — |
| FY2019 | — | $140M | $29M | $11M | — | — |
| FY2018 | — | $69M | $0 | $13M | — | — |
| FY2017 | — | $85M | $0.1M | $16M | — | — |
| FY2016 | — | $45M | $0.1M | $8M | — | — |
| FY2015 | — | $77M | $0.2M | $16M | — | $0 |
| FY2014 | — | $79M | $0.3M | $21M | — | $0 |
| FY2013 | — | $40M | $0.7M | $5M | — | $0.1M |
| FY2012 | — | $16M | $3M | $3M | — | $0.1M |
| FY2011 | — | $10M | $4M | $0.1M | — | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 11, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
- FY2014 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
- FY2015 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
- FY2016 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
- FY2017 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
- FY2018 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
- FY2019 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
- FY2020 net income derived as net income including minority interests (ProfitLoss) minus the minority share; the 10-K did not tag the parent figure.
Returns by year
| Year | TGTX | S&P 500 |
|---|---|---|
| 2019 | +170.7% | +31.5% |
| 2020 | +368.7% | +18.4% |
| 2021 | −63.5% | +28.7% |
| 2022 | −37.7% | −18.1% |
| 2023 | +44.4% | +26.3% |
| 2024 | +76.2% | +25.0% |
| 2025 | −1.0% | +17.9% |
| 2026 to date | +117.7% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Biotech
- MDGL Madrigal Down 8.1%
- CORT Corcept Therapeutics Down 20.1%
- KRYS Krystal Down 11%
- ARWR Arrowhead Down 15.3%
- ALNY Alnylam
- IOVA Iovance Down 35.4%
Show all 17
- TNGX Tango Therapeutics Down 16.4%
- SLS SELLAS Up 156.4%
- VKTX Viking Therapeutics
- GMAB Genmab Up 28.3%
- XNCR Xencor Up 15.9%
- VERA Vera Down 1.2%
- NRIX Nurix Therapeutics Down 38.2%
- AGIO Agios Down 9.9%
- IMCR Immunocore Up 9.1%
- MRNA Moderna Down 17.6%
- ORIC ORIC Pharmaceuticals Down 32%
Questions about TG Therapeutics
- How does TG Therapeutics make money?
- It sells one approved drug, Briumvi (ublituximab), for relapsing multiple sclerosis. In 2025 revenue was $616.3M, 96% of it from US sales through four specialty distributors; its partner Neuraxpharm sells Briumvi in licensed territories outside the US and pays royalties. More in the Long View →
- How does Briumvi compare with other MS drugs?
- Like Roche's Ocrevus and Novartis's Kesimpta, it is an anti-CD20 antibody: it targets CD20, a protein on certain B cells, and depletes those cells; its precise mechanism in MS is unknown. It is infused twice a year after the starting doses. More in the Long View →
- How long is Briumvi protected?
- It is eligible for 12 years of US biologic exclusivity from its approval, to December 2034. The original US composition-of-matter patent (covering the drug itself) expires in 2029, before any extension; newer US patents extend composition-of-matter protection to 2042. More in the Long View →
- What does TG depend on?
- One product, one licensor, one main manufacturer (Samsung Biologics) and one secured lender. TG sells mainly through four unnamed specialty distributors; the largest alone was 46% of gross product revenue in Q3 2026. More in the Long View →
- How has TG financed itself since Briumvi's launch?
- TG has raised money through share sales, an upfront licence payment from Neuraxpharm and secured borrowing. Its $750M loan in March 2026 refinanced a $250M loan, and it has spent $300M on buybacks since August 2024. More in the Long View →
Disclosure: one or more of our editors own shares of TG Therapeutics (TGTX) as a long-term investment.